[
  {
    "ts": null,
    "headline": "5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
    "summary": "There’s no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment. The dividend yield of the S&P 500 averages 1.2%, nearing its record low. Fortunately, there are several dividend stocks with a ... 5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
    "url": "https://finnhub.io/api/news?id=a8c10cb6793dfdf9b716d9feb81fe0904c8dccdd675eee04e61361f58c2ce1c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761678917,
      "headline": "5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
      "id": 137243714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "There’s no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment. The dividend yield of the S&P 500 averages 1.2%, nearing its record low. Fortunately, there are several dividend stocks with a ... 5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
      "url": "https://finnhub.io/api/news?id=a8c10cb6793dfdf9b716d9feb81fe0904c8dccdd675eee04e61361f58c2ce1c1"
    }
  },
  {
    "ts": null,
    "headline": "Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks",
    "summary": "Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market after the massive Artificial Intelligence rally that has driven the major indices to all-time highs over the last three years. Of course, ... Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks",
    "url": "https://finnhub.io/api/news?id=6858ed11b9a23c921d700f67334460c9d0cab4b7f2db109a6f4b85687cec88bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761675644,
      "headline": "Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks",
      "id": 137243435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market after the massive Artificial Intelligence rally that has driven the major indices to all-time highs over the last three years. Of course, ... Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks",
      "url": "https://finnhub.io/api/news?id=6858ed11b9a23c921d700f67334460c9d0cab4b7f2db109a6f4b85687cec88bd"
    }
  },
  {
    "ts": null,
    "headline": "3 Investable Laggards In An Overbought Market",
    "summary": "Discover three market sectors offering value amid overbought equities and tech-driven gains. Click for my top picks in several different sectors.",
    "url": "https://finnhub.io/api/news?id=688e4868dd78f3e5ea2449ff7ed6d59820a1a37b003e81fa177386bde350a205",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761671618,
      "headline": "3 Investable Laggards In An Overbought Market",
      "id": 137240626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193504232/image_2193504232.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover three market sectors offering value amid overbought equities and tech-driven gains. Click for my top picks in several different sectors.",
      "url": "https://finnhub.io/api/news?id=688e4868dd78f3e5ea2449ff7ed6d59820a1a37b003e81fa177386bde350a205"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=04785f89786dc530e6282f0d993ce28d8524123dc74cf65779ab2f66af89b540",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761669720,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
      "id": 137253841,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=04785f89786dc530e6282f0d993ce28d8524123dc74cf65779ab2f66af89b540"
    }
  },
  {
    "ts": null,
    "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
    "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
    "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660375,
      "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
      "id": 137240047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1940034961/image_1940034961.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
      "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807"
    }
  },
  {
    "ts": null,
    "headline": "Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer",
    "summary": "Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouil",
    "url": "https://finnhub.io/api/news?id=35309bf903f94a702a0cf3bbc6528f5a442db9d39d3f3bf37d15e05b697b0991",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761652800,
      "headline": "Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer",
      "id": 137237854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouil",
      "url": "https://finnhub.io/api/news?id=35309bf903f94a702a0cf3bbc6528f5a442db9d39d3f3bf37d15e05b697b0991"
    }
  },
  {
    "ts": null,
    "headline": "A Fresh Look at Bristol-Myers Squibb's Valuation After New Pipeline Progress and Phase 3 Sotyktu Results",
    "summary": "Bristol Myers Squibb (BMY) just reported new 52-week Phase 3 trial results for Sotyktu in adults with active psoriatic arthritis. The results show continuous clinical benefit, a steady safety profile, and evidence of joint damage limitation. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has been in the spotlight thanks to a steady stream of late-stage trial successes and high-profile partnerships, but the company’s share price reflects ongoing caution, with a 1-year...",
    "url": "https://finnhub.io/api/news?id=bb95f974f34712d51f3295d576132e1314f2e2c487073bacdea45fe118dd2ed2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761642999,
      "headline": "A Fresh Look at Bristol-Myers Squibb's Valuation After New Pipeline Progress and Phase 3 Sotyktu Results",
      "id": 137235649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) just reported new 52-week Phase 3 trial results for Sotyktu in adults with active psoriatic arthritis. The results show continuous clinical benefit, a steady safety profile, and evidence of joint damage limitation. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has been in the spotlight thanks to a steady stream of late-stage trial successes and high-profile partnerships, but the company’s share price reflects ongoing caution, with a 1-year...",
      "url": "https://finnhub.io/api/news?id=bb95f974f34712d51f3295d576132e1314f2e2c487073bacdea45fe118dd2ed2"
    }
  }
]